Clinical Trials Logo

Filter by:
NCT ID: NCT05087459 Recruiting - Thrombocytopenia Clinical Trials

Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular Carcinoma

Start date: June 30, 2021
Phase:
Study type: Observational

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world, accounting for the second leading cause of cancer death in China.Surgical treatment of hepatocellular carcinoma is the most important means for long-term survival of patients with hepatocellular carcinoma, including hepatectomy and liver transplantation.Chronic liver disease caused by hepatitis B infection is the main pathogenic factor of liver cancer in China. Meanwhile, nearly 80% of patients with hepatocellular carcinoma are complicated with cirrhosis, and the incidence of thrombocytopenia in patients with cirrhosis is reported to be as high as 78%.Many previous studies have found that thrombocytopenia is closely related to perioperative outcome of hepatocellular carcinoma.The purpose of this study was to evaluate the efficacy and safety of avatripopa in the treatment of thrombocytopenia in patients with primary hepatocellular carcinoma undergoing elective hepatectomy and its effect on perioperative outcome.

NCT ID: NCT05087264 Recruiting - Cervical Carcinoma Clinical Trials

Clinical Study of Indocyanine Green Displaying Pelvic Nerve in Radical Operation of Cervical Cancer

Start date: March 10, 2022
Phase: Early Phase 1
Study type: Interventional

Indocyanine green was injected intravenously into patients with cervical cancer before operation. The nerve development was observed by infrared imaging system during operation, which was used as the basis for nerve preserving operation of type C cervical cancer. The recovery of bladder function was observed.

NCT ID: NCT05087173 Recruiting - COVID-19 Clinical Trials

Effectiveness of Using Interactive Consulting System to Enhance Decision Aids of COVID-19 Vaccination

Start date: October 11, 2021
Phase: N/A
Study type: Interventional

To evaluate the performance of an interactive chatbot and assess its effectiveness for enhancing informed decisions made by cataract patients.

NCT ID: NCT05086666 Recruiting - Clinical trials for Urothelial Carcinoma

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Start date: June 3, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1b clinical study to evaluate the PK of oral AZD4547 in Chinese patients and RP2D. Phase 2 study to evaluate the efficacy of AZD4547 in urothelial carcinoma patients with FGFR2/3 gene alterations.

NCT ID: NCT05086627 Recruiting - Clinical trials for Locally Advanced Rectal Cancer

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

Start date: October 15, 2022
Phase: Phase 2
Study type: Interventional

This study is a single-center, prospective, open-label, randomized controlled clinical study, and the purpose of this study was to compare the pathological complete response rate (PCR) of patients with locally advanced rectal cancer treated with short-course radiotherapy sequential Tislelizumab combined with CapeOX (group A) versus short-course radiotherapy sequential CapeOX (group B). A total of 100 patients with locally advanced rectal cancer will be enrolled in the study. These patients were randomly assigned to the experimental group (group A) and the control group (group B) in a ratio of 1:1.

NCT ID: NCT05086614 Recruiting - Clinical trials for Stage III Colorectal Cancer

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Start date: April 1, 2021
Phase: Phase 3
Study type: Interventional

For high-risk stage II and stage III colorectal cancer, even after radical resection and postoperative adjuvant chemo/radiotherapy, 30-40% of patients will still have recurrence and metastasis. Thymosin-alpha 1 is believed to improve immunity and may help promote tumor immunity to reduce the incidence of recurrence and metastasis. This study hopes to verify the effecacy and safety of thymosin-alpha 1 for adjuvant treatment of high-risk stage II and stage III colorectal cancer after radical resection.

NCT ID: NCT05086601 Recruiting - Colorectal Cancer Clinical Trials

A Cohort of Molecular Characteristics and Prognosis of Colorectal Cancer

Start date: December 1, 2020
Phase:
Study type: Observational [Patient Registry]

This study aims to establish a colorectal cancer cohort, collect clinicopathological information, collect biological samples for multi-omics testing, and perform relevant analysis, to predict the prognosis of colorectal cancer, guide the diagnosis and treatment of colorectal cancer and the formulation of health policies.

NCT ID: NCT05086484 Recruiting - Endometriosis Clinical Trials

Omics Sequencing of Specimen Derived From Patients With Endometriosis

Start date: January 1, 2019
Phase:
Study type: Observational

Endometriosis is a type of chronic inflammatory gynecological disease, mainly took place in peritoneal cavity. In order to investigate the possible correlation between microbes and endometriosis, the investigators planed to perform 16S rDNA amplicon sequencing, metagenomic sequencing and metabolomic sequencing of paired samples derived from feces, cervical mucus, blood and peritoneal fluid.

NCT ID: NCT05086458 Recruiting - Gut Microbiota Clinical Trials

Impact of Probiotics Supplement on the Gut Microbiota in Caesarean-born Infants

Start date: August 17, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of probiotics on the gut microbiota of infants born by cesarean section.

NCT ID: NCT05086315 Recruiting - Clinical trials for Myelodysplastic Syndromes

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Start date: December 8, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological malignancies.